Company news
Sellas Life Sciences Group, Inc. (NASDAQ:SLS) news
Sellas Life Sciences Group, Inc. news releases on 6ix. Latest, Feb 23, 2023: SELLAS Life Sciences Announces Proposed Underwritten Public Offering
Press releases — page 3
SELLAS Life Sciences Announces Proposed Underwritten Public Offering
February 22, 2023
SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
January 18, 2023
SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
January 4, 2023
SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies
December 12, 2022
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
December 7, 2022
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
December 5, 2022
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results
November 13, 2022
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
November 13, 2022
SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Adv...
November 9, 2022
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
November 2, 2022
SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
October 16, 2022
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
October 10, 2022
SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
September 21, 2022
SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of Directors
August 15, 2022
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results
August 10, 2022
SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
July 6, 2022
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
June 26, 2022
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
June 7, 2022
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
May 25, 2022
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
April 25, 2022
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
April 10, 2022
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
April 5, 2022
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
April 4, 2022
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
March 30, 2022
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
March 30, 2022
SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
March 13, 2022
SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation
February 27, 2022
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
January 31, 2022
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China
January 25, 2022
SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer
January 4, 2022
SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation
November 22, 2021
SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 11, 2021
SELLAS Life Sciences Announces Settlement of Derivative Litigation
September 22, 2021
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 11, 2021
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
July 27, 2021
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo
June 23, 2021
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
June 21, 2021
SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies
May 26, 2021
SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 12, 2021
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update
March 22, 2021
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications
December 20, 2020
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
December 16, 2020
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
December 12, 2020
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
December 10, 2020
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China
December 6, 2020
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results
November 12, 2020
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
September 8, 2020
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
August 12, 2020
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
July 30, 2020